Thomas Soloway
Director/Miembro de la Junta en THIRD HARMONIC BIO, INC. .
Fortuna: - $ al 30/04/2024
Cargos activos de Thomas Soloway
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| THIRD HARMONIC BIO, INC. | Director/Miembro de la Junta | 01/07/2022 | - |
| Independent Dir/Board Member | 01/07/2022 | - | |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Director Ejecutivo | 19/01/2021 | - |
| T-Knife Therapeutics, Inc. | Director Ejecutivo | - | - |
Historial de carrera de Thomas Soloway
Antiguos cargos conocidos de Thomas Soloway.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 02/07/2020 | 08/06/2023 |
| Independent Dir/Board Member | 02/07/2020 | 08/06/2023 | |
| ASCENDIS PHARMA A/S | Director Financiero/CFO | 01/01/2014 | 01/09/2015 |
| Contacto de Relaciones con Inversores | 01/01/2014 | 01/02/2019 | |
| Public Communications Contact | 01/01/2014 | 01/02/2019 | |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Comptroller/Controller/Auditor | 01/02/2009 | 07/05/2012 |
| Director de Operaciones | 01/02/2009 | 01/12/2013 | |
| Director Financiero/CFO | 01/02/2009 | 07/05/2012 | |
| Fundador | 01/01/2002 | 01/12/2013 | |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director/Miembro de la Junta | 30/01/2009 | 06/02/2009 |
Montreux Equity Partners, Inc.
 Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Corporate Officer/Principal | 01/01/1993 | - |
| AUDENTES THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 29/09/2015 | 15/01/2020 |
| Director de Operaciones | - | - | |
| Director Financiero/CFO | 29/09/2015 | - | |
| Treasurer | 15/01/2020 | - | |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
Formación de Thomas Soloway.
| University of Southern California | Undergraduate Degree |
| Georgetown University | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 11 |
| Dinamarca | 2 |
| Alemania | 2 |
Operativa
| Chief Operating Officer | 3 |
| Director of Finance/CFO | 3 |
| Director/Board Member | 3 |
Sectorial
| Health Technology | 9 |
| Consumer Services | 3 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| PARATEK PHARMACEUTICALS, INC. | Health Technology |
| THIRD HARMONIC BIO, INC. | Health Technology |
| Empresas privadas | 7 |
|---|---|
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Montreux Equity Partners, Inc.
Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Finance |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
| T-Knife Therapeutics, Inc. |
- Bolsa de valores
- Insiders
- Thomas Soloway
- Experiencia